In Brief
- Aleniglipron pill led to up to 12.1% weight loss in 36 weeks.
- It offers a non-injectable, once-daily alternative to current GLP-1 drugs.
- Aleniglipron is a small molecule effective with or without food.
- The pill could be produced more easily at scale than injectables.
A new experimental pill named aleniglipron, a GLP-1 receptor agonist, has shown promising results in weight loss among people with obesity or overweight. Participants taking the pill lost up to 12.1% of their body weight over 36 weeks.
This oral medication differs from existing GLP-1 drugs such as Wegovy and Ozempic, which require injections. Aleniglipron is a small molecule taken once daily with or without food, potentially improving patient adherence.
Experts emphasize that the pill's mode of administration and simpler production process could facilitate easier access and larger scale manufacturing compared to injectable treatments. This innovation may provide a more convenient and scalable option for weight management in the future.
